Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis

Affiliations

¹ University of Michigan School of Medicine, Ann Arbor, Michigan.
² Inserm 9501 and 1116, Centre d'Investigations Cliniques, Nancy, France; CHU Nancy, Institut Lorrain du Coeur et des Vaisseaux, Vandoeuvre lès Nancy, Nancy, France; Université de Lorraine, Nancy, France; Association Lorraine pour le Traitement de l'Insuffisance Rénale, Vandoeuvre lès Nancy, Nancy, France. Electronic address: p.rossignol@chu-nancy.fr.

Free article

Editorial

Bertram Pitt et al. J Am Coll Cardiol. 2014.

Free article

. 2014 Feb 18;63(6):537-8.

doi: 10.1016/j.jacc.2013.09.057. Epub 2013 Oct 30.

¹ University of Michigan School of Medicine, Ann Arbor, Michigan.
² Inserm 9501 and 1116, Centre d'Investigations Cliniques, Nancy, France; CHU Nancy, Institut Lorrain du Coeur et des Vaisseaux, Vandoeuvre lès Nancy, Nancy, France; Université de Lorraine, Nancy, France; Association Lorraine pour le Traitement de l'Insuffisance Rénale, Vandoeuvre lès Nancy, Nancy, France. Electronic address: p.rossignol@chu-nancy.fr.

No abstract available

Keywords: cardiovascular and cerebrovascular event; hemodialysis; spironolactone.

Comment on

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.
Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N. Matsumoto Y, et al. J Am Coll Cardiol. 2014 Feb 18;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24184249 Clinical Trial.